MBX生物科技
MBX
49.61
-1.10
-2.17%
MBX生物科技
US · MBX
#2567 按市值排名
上市于 2024
49.61
-1.10
-2.17%
实时 - 追踪5344个代码 - 心跳于231秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了2.0个百分点。
机构持股
- 机构持股比例
- 115.55% -1.95pp
- 机构数量
- 205
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund54.54%
VC/PE Fund37.09%
Hedge Fund21.02%
Individual/Insider2.74%
Public Company2.24%
Government Pension Fund0.24%
Insurance Company0.19%
Private Company0.17%
主要股东 截至 2026-08-06
Frazier Life Sciences Management, LP
13.81% · 6.65M 股
FMR
11.05% · 5.32M 股
Wellington Management Group
10.34% · 4.98M 股
New Enterprise Associates, Inc.
7.51% · 3.61M 股
BlackRock
6.90% · 3.32M 股
OrbiMed Advisors LLC
6.38% · 3.07M 股
Paradigm Biocapital Advisors LP
5.21% · 2.51M 股
NVP Associates, LLC
4.44% · 2.14M 股
Deep Track Capital, LP
3.60% · 1.73M 股
Vanguard Capital Management, LLC
3.49% · 1.68M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 17次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 13.81% |
| Wellington Management Group | -- | 10.34% |
| Peter Hawryluk | Chief Executive Officer | 2.52% |
| Richard Bartram | Chief Financial Officer | 0.10% |
| Ora Pescovitz | Independent Director | 0.05% |
| Steven Hoerter | Independent Director | 0.04% |
| Salomon Azoulay | Chief Medical Officer | 0.03% |
| Patrick Heron | Independent Director | -- |
| OrbiMed Advisors LLC | -- | -- |
| James Cornelius | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-16 | Peter Hawryluk | Chief Executive Officer | Intent to Sell (Form 144) | -3,745 | $68.29 |
| 2026-08-03 | Peter Hawryluk | Chief Executive Officer | Intent to Sell (Form 144) | -936 | $65.77 |
| 2026-08-03 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -370 | $65.77 |
| 2026-08-02 | John Smither | Interim Chief Financial Officer | Other Acquisition | +28,000 | -- |
| 2026-08-02 | John Smither | Interim Chief Financial Officer | Other Derivative Acquisition | +130,000 | $64.41 |
| 2026-08-02 | Steven Hoerter | Independent Director | Other Acquisition | +71,000 | -- |
| 2026-08-02 | Steven Hoerter | Independent Director | Other Derivative Acquisition | +331,000 | $64.41 |
| 2026-06-09 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -9,167 | $30.55 |
| 2026-06-08 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -10,833 | $29.66 |
| 2026-06-03 | Patrick Heron | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Edward Mathers | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Ora Pescovitz | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Tiba Aynechi | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Ryder | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Hoerter | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Laurie Stelzer | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-05-12 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $36.95 |
| 2026-05-10 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -22,500 | $44.08 |
| 2026-05-07 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -10,000 | $37.96 |
| 2026-05-07 | Salomon Azoulay | Chief Medical Officer | Derivative Exercise and Sale | -70,003 | $10.46–38.38 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
MBX生物科技 讨论区 0 条评论